Skip to content

Transcranial Direct Current Stimulation as Home Treatment in Depression

GleichStrom UND Depression: Anwendung zu Hause Ohne Anreise Zur Medbo (Transcranial Direct Current Stimulation and Depression: Home Treatment)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05123872
Acronym
GSUND_DAHOAM
Enrollment
10
Registered
2021-11-17
Start date
2021-11-01
Completion date
2023-04-30
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Brief summary

In this one-armed study the feasibility and effectiveness of a home treatment with transcranial direct currect stimulation in depression will be investigated.

Detailed description

In this one-armed study at least 10 patients with depression will be included who will get treatment with transcranial direct currect stimulation at home. One visit in the hospital before and one visit after the treatment are necessary. The correct application of the device by the patients will be ensured by video counseling and monitoring. Treatment will last six weeks with 2 mA applied every working day for 20min with prefrontal montage. Aim of the study is the evaluation of the feasibility of this home treatment (usability of the device, compliance of patients, usability of the video contacts), the effectiveness (clinical ratings) and the tolerability of this treatment.

Interventions

DEVICEtDCS

trancranial direct current stimulation 30 sessions within 6 weeks (treatment on working days) 2mA with cathode on the right and anode an the left side

Sponsors

neurocare group AG
CollaboratorUNKNOWN
University of Regensburg
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* depressive episode according to ICD-10 * moderate depression according to clinical impression or Hamilton depression rating scale * gender: all sexes * age: 18-70 years * stable medication if possible * no or stable treatment of depression * residence in Germany and mother language German * written informed consent

Exclusion criteria

* contraindications for transcranial direct current stimulation * neurological conditions * participiation in another study * pregnancy and lactation period

Design outcomes

Primary

MeasureTime frameDescription
Stability of effects 2 (Effect size for change of depressivity for patients in the per protocol analysis measured with the Hamilton depression rating scale (21 items))18 weeksEffect size for change of depressivity for patients in the per protocol analysis measured with the Hamilton depression rating scale (21 items)
Usability for the patients6 weeksRating of the usability of the treatment (home treatment and video monitoring) with the user experience questionnaire \[1-7, 26 items, the higher the better\] and open feedback
Usability for the handlers/clinicians6 weeksRating of the usability of the treatment (home treatment and video monitoring) with the user experience questionnaire \[1-7, 26 items, the higher the better\] and open feedback
Compliance 1 (Number of days out of 30 the patients used the device)6 weeksNumber of days out of 30 the patients used the device
Compliance 2 (Number of patients who completed the treatment regulary)6 weeksNumber of patients who completed the treatment regulary
Efficiancy 1 (Number of responders according the the clinical global impression change score for patients in the per protocol analysis)6 weeksNumber of responders according the the clinical global impression change score for patients in the per protocol analysis
Efficiancy 2 (Effect size for change of depressivity for patients in the per protocol analysis measured with the Hamilton depression rating scale (21 items))6 weeksEffect size for change of depressivity for patients in the per protocol analysis measured with the Hamilton depression rating scale (21 items)
Stability of effects 1 (Number of responders according the the clinical global impression change score)18 weeksNumber of responders according the the clinical global impression change score

Secondary

MeasureTime frameDescription
Major Depression Inventory18 weeksDepression inventory (0-50, the lower the better)
WHO Quality of life scale (abbreviated Version) (WHOQOL-BREF)18 weeksQuality of life scale inventory (4-20, the higher the better)
Clincial Global Impression change18 weeksClincial Global Impression (1-7, the lower the better)
Pittsburgh sleep quality index18 weekssleep inventory (0-21, the lower the better)
Depression anxiety stress scale (DASS)18 weeksDepression, anxiety and stress inventory (each 0-21, the lower the better)
Personality styles and disorder inventory18 weeksDepedence of treatment effect from personality as measured with the Personality styles and disorder inventory (PSDI) (T-value norms, values around 50 are normal)
Hamilton depression rating scale18 weeksDepression rating scale (0-65, the lower the better)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026